(JRVR) James River Holdings - Overview
Stock: Excess, Surplus, Liability, Property, Fronting
| Risk 5d forecast | |
|---|---|
| Volatility | 51.4% |
| Relative Tail Risk | -11.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.24 |
| Alpha | 51.67 |
| Character TTM | |
|---|---|
| Beta | 0.454 |
| Beta Downside | 0.519 |
| Drawdowns 3y | |
|---|---|
| Max DD | 83.27% |
| CAGR/Max DD | -0.39 |
EPS (Earnings per Share)
Revenue
Description: JRVR James River Holdings February 26, 2026
James River Group Holdings, Inc. (NASDAQ: JRVR) is a specialty insurer operating two primary segments: Excess and Surplus Lines, which underwrites liability and property coverage across the United States, Puerto Rico, and the U.S. Virgin Islands via wholesale brokers; and Specialty Admitted Insurance, which supplies fronting, program administration, and managing general agent solutions. Founded in 2002 and based in Chapel Hill, NC, the firm focuses on niche markets that larger carriers often avoid.
In its most recent fiscal quarter (Q3 2024), JRVR reported net written premium of $124 million, a 9% year-over-year increase, and a combined ratio of 94.2%, indicating underwriting profitability. The company posted adjusted earnings per share of $0.38 and a market capitalization of approximately $1.1 billion, reflecting steady investor confidence in its specialized business model.
The property-and-casualty sector is currently driven by rising insurance rates tied to inflation, heightened natural-catastrophe exposure, and a hardening market cycle that favors surplus-lines carriers. JRVR’s focus on wholesale distribution and niche admitted lines positions it to capture premium growth as commercial clients seek tailored coverage amid these macro-economic pressures.
For a deeper dive into JRVR’s valuation and risk profile, you might explore the analysis tools available on ValueRay.
Headlines to watch out for
- E&S segment premium growth drives revenue
- Specialty Admitted segment performance impacts profitability
- Catastrophe losses increase underwriting expenses
- Regulatory changes affect insurance product offerings
- Interest rate fluctuations impact investment income
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 47.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 4.59 > 1.0 |
| NWC/Revenue: -498.5% < 20% (prev 223.9%; Δ -722.5% < -1%) |
| CFO/TA -0.00 > 3% & CFO -12.0m > Net Income 47.4m |
| Net Debt (68.9m) to EBITDA (74.4m): 0.93 < 3 |
| Current Ratio: 0.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.1m) vs 12m ago 45.75% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 17.81% > 50% (prev 14.13%; Δ 3.68% > 0%) |
| Interest Coverage Ratio: 1.85 > 6 (EBITDA TTM 74.4m / Interest Expense TTM 23.5m) |
Altman Z'' -8.85
| A: -1.26 (Total Current Assets 423.1m - Total Current Liabilities 3.85b) / Total Assets 2.72b |
| B: -0.13 (Retained Earnings -364.7m / Total Assets 2.72b) |
| C: 0.01 (EBIT TTM 43.6m / Avg Total Assets 3.86b) |
| D: -0.20 (Book Value of Equity -399.5m / Total Liabilities 2.04b) |
| Altman-Z'' Score: -8.85 = D |
Beneish M
| DSRI: 0.07 (Receivables 153.6m/2.36b, Revenue 687.6m/707.6m) |
| GMI: 0.34 (GM 99.95% / 33.73%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 0.97 (Revenue 687.6m / 707.6m) |
| TATA: 0.02 (NI 47.4m - CFO -12.0m) / TA 2.72b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of JRVR shares?
Over the past week, the price has changed by -1.08%, over one month by -6.84%, over three months by -5.74% and over the past year by +60.01%.
Is JRVR a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the JRVR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.7 | 19.7% |
| Analysts Target Price | 7.7 | 19.7% |
JRVR Fundamental Data Overview March 14, 2026
P/S = 0.4325
P/B = 0.5878
Revenue TTM = 687.6m USD
EBIT TTM = 43.6m USD
EBITDA TTM = 74.4m USD
Long Term Debt = 329.9m USD (from longTermDebt, two quarters ago)
Short Term Debt = unknown (none)
Debt = 329.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 68.9m USD (from netDebt column, last quarter)
Enterprise Value = -1.04b USD (297.4m + Debt 329.9m - CCE 1.67b)
Interest Coverage Ratio = 1.85 (Ebit TTM 43.6m / Interest Expense TTM 23.5m)
EV/FCF = 86.70x (Enterprise Value -1.04b / FCF TTM -12.0m)
FCF Yield = 1.15% (FCF TTM -12.0m / Enterprise Value -1.04b)
FCF Margin = -1.74% (FCF TTM -12.0m / Revenue TTM 687.6m)
Net Margin = 6.90% (Net Income TTM 47.4m / Revenue TTM 687.6m)
Gross Margin = unknown ((Revenue TTM 687.6m - Cost of Revenue TTM 363k) / Revenue TTM)
Tobins Q-Ratio = -0.38 (set to none) (Enterprise Value -1.04b / Total Assets 2.72b)
Interest Expense / Debt = 1.81% (Interest Expense 5.97m / Debt 329.9m)
Taxrate = 6.17% (3.12m / 50.5m)
NOPAT = 40.9m (EBIT 43.6m * (1 - 6.17%))
Current Ratio = 0.11 (Total Current Assets 423.1m / Total Current Liabilities 3.85b)
Debt / Equity = 0.61 (Debt 329.9m / totalStockholderEquity, last quarter 538.2m)
Debt / EBITDA = 0.93 (Net Debt 68.9m / EBITDA 74.4m)
Debt / FCF = -5.75 (negative FCF - burning cash) (Net Debt 68.9m / FCF TTM -12.0m)
Total Stockholder Equity = 604.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.23% (Net Income 47.4m / Total Assets 2.72b)
RoE = 7.85% (Net Income TTM 47.4m / Total Stockholder Equity 604.5m)
RoCE = 4.66% (EBIT 43.6m / Capital Employed (Equity 604.5m + L.T.Debt 329.9m))
RoIC = 4.96% (NOPAT 40.9m / Invested Capital 823.4m)
WACC = 4.49% (E(297.4m)/V(627.3m) * Re(7.59%) + D(329.9m)/V(627.3m) * Rd(1.81%) * (1-Tc(0.06)))
Discount Rate = 7.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 26.34%
[DCF] Fair Price = unknown (Cash Flow -12.0m)
EPS Correlation: -44.36 | EPS CAGR: -5.44% | SUE: -0.19 | # QB: 0
Revenue Correlation: -41.10 | Revenue CAGR: -4.83% | SUE: -0.01 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.30 | Chg7d=+0.009 | Chg30d=+0.009 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=1.18 | Chg7d=-0.012 | Chg30d=-0.012 | Revisions Net=-1 | Growth EPS=+15.0% | Growth Revenue=-1.7%
EPS next Year (2027-12-31): EPS=1.22 | Chg7d=+0.031 | Chg30d=+0.031 | Revisions Net=-1 | Growth EPS=+2.9% | Growth Revenue=+0.7%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)